129013-83-8

Usage

Chemical Properties

Pale yellow liquid

InChI:InChI=1/C11H8BrN/c12-11-5-3-9(4-6-11)10-2-1-7-13-8-10/h1-8H

Upstream product

• 1008-88-4 3-phenylpyridine 
• 589-87-7 1,4-bromoiodobenzene 
• 59020-09-6 3-(trimethylstannyl)pyridine 
• 626-55-1 3-Bromopyridine 
• 110-86-1 pyridine 
• 39795-60-3 4-(4-bromophenyl)pyridine 
• 1692-25-7 3-pyridylboronic acid 
• 4385-75-5 4-(pyridine-3-yl)benzoic acid 
• 106-37-6 1.4-dibromobenzene 
• 622-88-8 4-bromophenylhydrazine hydrochloride 
• 63996-36-1 2-(4-bromophenyl]pyridine 
• 72287-26-4 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 
• 497-19-8 sodium carbonate 
• 131534-65-1 pyridine-3-boronic acid 1,3-propanediol cyclic ester 

Downstream Products

• 247214-56-8 3-[4’-(diethylboryl)phenyl]pyridine 
• 181133-19-7 N-(3,4-Dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-4'-(3-pyridinyl)[1,1'-biphenyl]-2-sulfonamide 
• 1159296-27-1 2-phenyl-3-[4'-(3-pyridyl)biphenyl-4-yl]quinoxaline 
• 941585-41-7 7(S)-1′-N-(tert-butoxycarbonyl)-1′-demethyl-7-deoxy-7-{4-(pyridin-3-yl)phenylthio}lincomycin 
• 921205-02-9 1,3,5-tris[4-(pyridin-3-yl)phenyl]benzene 
• 1196713-67-3 2-[4-((3S)-(tertbutoxycarbonyl)piperidin-3-yl)phenyl]-2H-indazole-7-carboxylic acid methyl ester 
• 1476776-55-2 (S)-3-(4-bromophenyl)piperidine-1-carboxylic acid tert-butyl ester 
• 1335523-82-4 4-(3S-piperidine-3-yl)bromobenzene 
• 941587-80-0 7(S)-7-deoxy-7-(4-(pyridin-3-yl)phenythio)lincomycin 
• 1088408-68-7 7(S)-7-deoxy-7-(4-(1-methylpiperidin-3-yl)phenylthio)lincomycin 
• 1088408-66-5 7(S)-7-deoxy-7-(4-(piperidin-3-yl)phenylthio)lincomycin 

Relevant academic research and scientific papers

Chiral Self-Discrimination and Guest Recognition in Helicene-Based Coordination Cages

Chiral nanosized confinements play a major role for enantioselective recognition and reaction control in biological systems. Supramolecular self-assembly gives access to artificial mimics with tunable sizes and properties. Herein, a new family of [Pd2L4] coordination cages based on a chiral [6]helicene backbone is introduced. A racemic mixture of the bis-monodentate pyridyl ligand L1 selectively assembles with PdII cations under chiral self-discrimination to an achiral meso cage, cis-[Pd2L1P2L1M2]. Enantiopure L1 forms homochiral cages [Pd2L1P/M4]. A longer derivative L2 forms chiral cages [Pd2L2P/M4] with larger cavities, which bind optical isomers of chiral guests with different affinities. Owing to its distinct chiroptical properties, this cage can distinguish non-chiral guests of different lengths, as they were found to squeeze or elongate the cavity under modulation of the helical pitch of the helicenes. The CD spectroscopic results were supported by ion mobility mass spectrometry.

Phototautomerization in Pyrrolylphenylpyridine Terphenyl Systems

[4-(2-Pyrrolyl)phenyl]pyridines 2-4 were synthesized and their photophysical properties and reactivity in phototautomerization reactions investigated by fluorescence spectroscopy and laser flash photolysis (LFP). The pKa for the protonation of the pyridine nitrogen in 2-4 was determined by UV-vis and fluorescence titration (pKa = 5.5 for 4). On excitation in polar protic solvents, 2-4 populate charge-transfer states leading to an enhanced basicity of the pyridine (pKa? ≈ 12) and enhanced acidity of pyrrole (pKa? ≈ 8-9) enabling excited-state proton transfer (ESPT). ESPT gives rise to phototautomers and significantly quenches the fluorescence of 2-4. Phototautomers 2-T and 4-T were detected by LFP with strong transient absorption maxima at 390 nm. Phototautomers 2-T and 4-T decayed by competing uni- and bimolecular reactions. However, at pH 11 the decay of 4-T followed exponential kinetics with a rate constant of 4.2 × 106 s-1. The pyridinium salt 4H+ forms a stable complex with cucurbit[7]uril (CB[7]) with 1:1 stoichiometry (β11 = (1.0 ± 0.2) × 105 M-1, [Na+] = 39 mM). Complexation to CB[7] increased the pKa for 4H+ (pKa = 6.9) and changed its photochemical reactivity. Homolytic cleavage of the pyrrole NH leads to the formation of an N-radical because of the decreased acidity of the pyrrole in the inclusion complex. (Figure Presented).

INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR

Disclosed is a type of indolo heptamyl oxime compounds as a PARP inhibitor. Specifically disclosed are a compound as represented by formula (II) and a pharmaceutically acceptable salt thereof.

Catalytic Enantioselective Synthesis of Pyridyl Sulfoximines

With unique chemical and biological activity, sulfoximines have attracted enormous attention in the past decades, whereas limited reports exist for their synthesis via asymmetric catalysis. We report the synthesis of chiral sulfoximines through the desymmetrizing N-oxidation of pyridyl sulfoximines using an aspartic acid-containing peptide catalyst. Various mono- and bis-pyridyl sulfoximine oxides are obtained with up to 99:1 er. The directing group introduced on the substrate highly enhances the enantioinduction and could be easily removed to give the free N-H sulfoximines. Additionally, peptides with methyl ester and the methyl amide C-terminal protecting group give the opposite enantiomers of the product. A binding model is proposed to explain this phenomenon.

Compound with AMPK agonistic activity and preparation and application of prodrug thereof

The invention relates to a compound with AMPK agonistic activity and a prodrug thereof, and as well as a preparation method and medical application of a prodrug thereof. The compound has the structure shown in the formula (I), and the prodrug of the compound has the structure shown in the formula (II), wherein each group and the substituent are as defined in the specification. The invention discloses a preparation method of the compound and application of the compound in prevention and treatment AMPK related diseases, and the AMPK related diseases include, but are not limited to, energy metabolism abnormality related diseases. Neurodegenerative diseases and inflammation-related diseases and the like.

Dianthracene compound containing pyridyl at tail end and application thereof

The invention provides dianthracene compounds shown in a general formula I in the specification. In the general formula I, L1 and L2 represent single bonds, substituted or unsubstituted heterocyclic aromatic groups of C2-C60 or substituted or unsubstituted hydrocarbon aromatic groups of C6-C60; L3 represents a substituted or unsubstituted heterocyclic aromatic group of C2-C60 or a substituted or unsubstituted hydrocarbon aromatic group of C6-C60; L1, L2 and L3 are shown in a formula in the specification at different time; R10, R18, R21 and R23-R28 represent hydrogen, halogen and substituted or unsubstituted alkyl or alkoxy of C1-C10. The compounds have good luminescence properties, high electron transport capacities and terrific solubility and can be used in luminescent materials, electron transport materials and hole-blocking materials in the electroluminescence field. The invention also provides an organic electroluminescence device at least comprising a pair of electrodes and organic luminescent media between the electrodes. The organic luminescent media at least comprise the dianthracene compounds.

Dianthracene compound containing pyridyl at tail end and application thereof

The invention provides dianthracene compounds shown in a general formula I in the specification. In the general formula I, L1 and L2 independently represent single bonds, substituted or unsubstituted heterocyclic aromatic groups of C2-C60 or substituted or unsubstituted hydrocarbon aromatic groups of C6-C60; L3 represents a substituted or unsubstituted heterocyclic aromatic group of C2-C60 or a substituted or unsubstituted hydrocarbon aromatic group of C6-C60; R10, R11, R12, R13, R14, R15, R16, R17, R18, R21, R23, R24, R25, R26, R27 and R28 independently represent hydrogen, halogen and substituted or unsubstituted alkyl or alkoxy of C1-C10. The compounds have good luminescence properties, high electron transport capacities and terrific solubility and can be used in luminescent materials, electron transport materials and hole-blocking materials in the electroluminescence field. The invention also provides an organic electroluminescence device at least comprising a pair of electrodes and organic luminescent media between the electrodes. The organic luminescent media at least comprise the dianthracene compounds.

Visible-Light-Photosensitized Aryl and Alkyl Decarboxylative Functionalization Reactions

Despite significant progress in aliphatic decarboxylation, an efficient and general protocol for radical aromatic decarboxylation has lagged far behind. Herein, we describe a general strategy for rapid access to both aryl and alkyl radicals by photosensitized decarboxylation of the corresponding carboxylic acids esters followed by their successive use in divergent carbon–heteroatom and carbon–carbon bond-forming reactions. Identification of a suitable activator for carboxylic acids is the key to bypass a competing single-electron-transfer mechanism and “switch on” an energy-transfer-mediated homolysis of unsymmetrical σ-bonds for a concerted fragmentation/decarboxylation process.

Bipyridyl derivative and application thereof

The present invention provides a novel compound, which has a structure general formula represented by a formula (I), wherein Ar1 and Ar2 are independently selected from an aromatic hydrocarbon derivative group containing benzimidazoyl, an aromatic hydrocarbon derivative group containing a pyridine group, substituted or unsubstituted C6-C30 aromatic hydrocarbon, and a substituted or unsubstituted C6-C30 fused ring aromatic hydrocarbon group, and R1 and R2 are independently and respectively selected from H, C1-C12 aliphatic hydrocarbon radical, phenyl, substituted phenyl, naphthyl, substituted naphthyl, biphenyl and substituted biphenyl. According to the present invention, the compound has characteristics of stable character, simple preparation process, high luminous efficiency and high carrier mobility, and can be used for the electron transport layer of the electroluminescent element, and the device applying the compound has characteristics of significant driving voltage reducing and current efficiency improving. The formula (I) is defined in the instruction.

Preparation method of niraparib tosilate monohydrate

The invention discloses a preparation method of a compound 2-[4-((3S)-3-piperidyl)phenyl]-2H-indazole-7-formamide tosilate monohydrate. The method includes: carrying out Ulman reaction on 1H-indazole-7-methyl formate and (S)-3-(4-halogenophenyl)piperidine-1-tert-butyl formate to prepare 2-[4-((3S)-3-piperidyl)phenyl]-2H-indazole-7-methyl formate, then under the conditions of ammonia gas and p-toluenesulfonic acid, preparing 2-[4-((3S)-3-piperidyl)phenyl]-2H-indazole-7-formamide tosilate monohydrate. The invention aims to avoid the disadvantages of existing methods, shortens the preparation route, and provides the preparation method of the 2-[4-((3S)-3-piperidyl)phenyl]-2H-indazole-7-formamide tosilate monohydrate with high chiral purity, and the method has the characteristics of mild reaction and easy operation.